Investors

Financials & Filings

Filing date Form Description Filing Group View
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
UPLOAD

UPLOAD

Other
PRER14A

Proxy soliciting materials. Revised preliminary material

Proxy Filings
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
CORRESP

CORRESP

Other
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
UPLOAD

UPLOAD

Other
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.